AtaiBeckley Inc. (NASDAQ:ATAI) shares held steady at $7.17 as of 1 p.m. EDT on Tuesday, July 28, 2026, reflecting a 42-cent premium over Eli Lilly and Co.'s (NYSE:LLY) $6.75 cash offer at closing. The gap values the contingent value rights (CVR) at 42 cents, representing 16.8% of their $2.50 maximum payout. This calculation assumes deal closure and does not account for time value or closing risk.
Deal Structure and CVR Mechanics
The CVR, which is not tradable on any exchange after the deal closes, is tied to three milestones. The first milestone, worth up to $1 per share, requires VLS-01 to advance to Phase 3 within four years, contingent on positive Phase 2 data and regulatory alignment. Two additional milestones offer potential payouts: a 50-cent payment within five years upon approval and DEA rescheduling of BPL-003, and a further $1 payment within seven years following approval and rescheduling of VLS-01.
Carole Ho, president of Lilly Neuroscience, stated, “Advancing AtaiBeckley’s investigational therapies gives us a real chance to change that.” Lilly estimates the initial equity value at approximately $2.8 billion, with the CVR offering an additional potential $1 billion.
Trading Activity and Volume
ATAI shares traded within a narrow range of $7.16 to $7.20 on Tuesday, with volume reaching 9.46 million shares—roughly 90% of its 65-day average. The stock’s stability reflects market confidence in the deal’s completion, though risks remain.
Key Stakeholders and Approvals
BlackRock Inc. (NYSE:BLK) reported ownership of 24.99 million shares, or 6.8% of AtaiBeckley, as of June 30, according to a Schedule 13G filing. The filing notes the stake is held in the ordinary course of business and not for control purposes, and does not indicate endorsement of the sale. Additionally, approximately 15% of shares have been committed by Apeiron Investment Group and AtaiBeckley insiders. The merger requires shareholder approval, and regulatory approvals are also pending.
Timeline and Risks
AtaiBeckley and Lilly anticipate closing the deal in the third quarter of 2026. AtaiBeckley expects to release VLS-01 Phase 2b data in the fourth quarter, which may be available after the scheduled close. However, risks persist: Lilly is only required to use commercially reasonable efforts for milestones, and the agreement does not guarantee any CVR payment. The cash payment of $7.17 constitutes approximately 94% of Tuesday’s quoted price, with the balance tied to milestone payments extending up to seven years.
Market Context
This acquisition offers AtaiBeckley shareholders a near-term cash value with potential upside from the CVR. The extended timeline for milestone payments shapes the deal’s nature, blending immediate liquidity with long-term speculative value. The implied CVR valuation of 16.8% of its maximum suggests market skepticism about milestone achievement, given the regulatory and clinical hurdles.
